Merck Raises 2019 Revenue, Adjusted Earnings Guidance
October 29 2019 - 8:02AM
Dow Jones News
By Dave Sebastian
Merck & Co. (MRK) raised its full-year outlook for revenue
and adjusted earnings.
The company now sees full-year revenue of $46.5 billion to $47
billion. It previously guided revenue of $45.2 billion to $46.2
billion. Analysts polled by FactSet are expecting $45.94
billion.
The guidance includes the impact of the Gardasil 9 human
papillomavirus infection vaccine stockpile borrowing from the
Centers for Disease and Control and Prevention, which is expected
to reduce Gardasil 9 sales in the fourth quarter by about $120
million, Merck said.
Merck cut its per-share earnings to between $3.75 and $3.80 from
between $3.78 and $3.88.
The company now expects adjusted per-share earnings to be
between $5.12 and $5.17, compared with its prior guidance of $4.84
to $4.94. Analysts are expecting $4.92 a share.
Merck also narrowed its guidance for its full-year effective tax
rate to about 16.5%, compared with its previously guided range of
16% to 17%. It narrowed its non-GAAP effective tax rate to about
17.5% from it previous guidance of 16.5% to 17.5%.
Merck reaffirmed its guidance for operating expenses to be
higher than 2018 by a low single digit rate.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
October 29, 2019 07:47 ET (11:47 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024